Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05082415
Other study ID # CRTH258AUS15
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 3, 2020
Est. completion date December 15, 2020

Study information

Verified date October 2021
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study was a retrospective cohort study of patients to assess the early insights into real-world safety among wet AMD patients initiating brolucizumab. Evidence was generated to describe their patient characteristics and clinical outcomes. The study was conducted using the IRIS Registry.


Description:

IRIS Registry EHR data from patients with wet AMD who initiated brolucizumab were analyzed in this study. Identification period of the index date (index period): The patients fulfilling the selection criteria was identified - Index date: Defined as the date of the earliest brolucizumab injection - Study Period: The period from the first patient eye exposure to brolucizumab to the last follow-up recorded - Pre-index period: The period 36 months prior to the index date. Data within 36 months prior to the index date will be used to assess baseline characteristics. - Post-index period: The period 180 days after the index date


Recruitment information / eligibility

Status Completed
Enrollment 9456
Est. completion date December 15, 2020
Est. primary completion date December 15, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. =1 Healthcare Common Procedure Coding System (HCPCS) code (J code) or EMR note for treatment with brolucizumab during the index period (date of earliest code or EMR note = index date) 2. =18 years old on the index date 3. =1 Current Procedural Terminology (CPT) code for intravitreal administration on the index date 4. =1 International Classification of Diseases, Clinical Modification-9/10 (ICD-9/10) code for wet AMD in the 36 months prior to or on the index date o Note: Off-label use of brolucizumab is not expected given payer access restrictions in the US. 5. =1 follow-up visit after the index date 6. =1 VA assessment on the index date or within 90 days prior to the index date Exclusion Criteria: 1. Use of brolucizumab prior to 10/8/2019 (e.g. clinical trials) 2. Unknown laterality of the index eye on the index date

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Brolucizumab
Participants received brolucizumab injection during the index period

Locations

Country Name City State
United States Novartis Pharmaceuticals East Hanover New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patient eyes with an Intraocular Inflammation (IOI) event during the first 6 months To assess IOI events observed after starting treatment with brolucizumab Up to 6 months post brolucizumab injection
Secondary Age Age information was reported At the brolucizumab index date defined as the date of first brolucizumab injection
Secondary Gender information Gender information was reported At the brolucizumab index date defined as the date of first brolucizumab injection
Secondary Number of patients at various Patient Region Patient regions: Northeast, Midwest, South, West, Unknown At the brolucizumab index date defined as the date of first brolucizumab injection
Secondary Number of patients with Insurance type Insurance type: Medicare, Medicare Advantage, Medicaid, Commercial, Government, Military, No Insurance, Miscellaneous, Unknown At the brolucizumab index date defined as the date of first brolucizumab injection
Secondary Number of patients with Laterality of wet Age-related macular degeneration (AMD) Laterality of wet AMD: Unilateral, Bilateral At the brolucizumab index date defined as the date of first brolucizumab injection
Secondary Race/Ethnicity of the participants (patient level and eye level) Caucasian, Black or African American, Asian, Other, Unknown At the brolucizumab index date defined as the date of first brolucizumab injection
Secondary Number of eyes with the concurrent eye disease Types of concurrent eye diseases: ? Cataracts
Posterior vitreous detachment
Puckering of macula
Macular hole
Vitreomacular traction
Glaucoma
Amblyopia
Papillitis
Ischemic optic atrophy
Diabetic retinopathy
Diabetic macular edema
Hypertensive retinopathy
Pathologic myopia
RAO
RO
RV
Vitritis
Endophthalmitis
Uveitis
Choroidal neovascularization (due to causes other than AMD, if possible, to determine)
IOI
Within 180 days prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection)
Secondary Number of patient eyes with cataract status Types: phakic, pseudophakic, aphakic 36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection)
Secondary Number of patient eyes with Concomitant ocular medications Types:
Corticosteroids
Prednisone
Prednisolone acetate
Difluprednate
Biologics
Cyclosporine
Methotrexate
Ganciclovir
Acyclovir
Trifluridine
Rituxan
36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection)
Secondary Number of patient eyes with the history of ocular inflammation The following categories were reported:
No history of inflammation
History of any ocular inflammation
History of severe ocular inflammation
History of anterior inflammation
History of posterior inflammation
History of IOI or endophthalmitis due to infections and other underlying disease (separate category)
36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection)
Secondary Number of patient eyes with prior Intraocular Inflammation (IOI) and/or prior Retinal vascular occlusion (RO) Included history of ocular inflammation or occlusion 12 months prior to the index date ( index date defined as the date of first brolucizumab injection)
Secondary Number of patient eyes with the Provider specialty The following types were included:
Retina specialist, General ophthalmologist, Non-retina specialist, unknown
At the brolucizumab index date defined as the date of first brolucizumab injection
Secondary Number of patient eyes with the previous ocular surgeries or procedures The following categories were included:
Laser therapy
Laser coagulation
Photodynamic therapy
IOP lowering surgeries (lasers, glaucoma filtering, non-filtering glaucoma)
Cataract surgery
Iridotomy
Intraocular or refractive surgery (almost all IOP & cataract surgeries)
Previous penetrating keratoplasty, vitrectomy, or ocular radiation
Previous panretinal photocoagulation
Previous submacular surgery, other surgical intervention or laser treatment for AMD
6 months prior to the index date ( index date defined as the date of first brolucizumab injection)
Secondary Number of eyes treated with brolucizumab The following types were included:
OD [eye, right], OS [eye, left], Unspecified, Unilateral, Bilateral)
At the brolucizumab index date defined as the date of first brolucizumab injection
Secondary Number of patient eyes with Visual Acuity (VA) reading The following categories were included:
Snellen: 20/10, 20/12-20/20, 20/25-20/40, 20/50-20/160, =20/200
Approximate ETDRS letters
At the brolucizumab index date defined as the date of first brolucizumab injection with lookback of 365 days
Secondary Number of patient eyes with Anti-VEGF treatment-naive vs prior-treated Anti-VEGF treatment-naive vs prior-treated were measured at the eye level 36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection)
Secondary Number of patient eyes with the prior treatment status The following types were included:
off-label bevacizumab, ranibizumab, aflibercept, unknown, treatment-naive
36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection)
Secondary Number of different prior anti-VEGF agents The following categories were measured at the eye level:
0, 1, 2, =3
36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection)
Secondary Number of prior anti-VEGF injections Total, per anti-VEGF agent were measured at the eye level)
Continuous
Categorical: <6, 6 to <12, 12 to <24, =24
36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection)
Secondary Duration of last anti-VEGF treatment Total, per anti-VEGF agent; will be measured at the eye level
All anti-VEGFs i. Continuous ii. Categorical: <6, 6 to <12, 12 to <24, =24 months
Specific anti-VEGF iii. Continuous iv. Categorical: <6, 6 to <12, 12 to <24, =24 months
36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection)
Secondary Time since wet Age-related macular degeneration (AMD) diagnosis Patients were measured at the eye level 36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection)
Secondary Time since any Age-related macular degeneration (AMD) diagnosis Patients were measured at the eye level 36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection)
Secondary Time from last anti-VEGF injection to index date (among switchers) The following categories were measured:
Continuous (days)
Categorical (0-30, 31-60, 61-90, 91+ days)
At the brolucizumab index date defined as the date of first brolucizumab injection
Secondary Number of ocular adverse events (AEs) To assess the incidence of ocular AEs among patients treated with brolucizumab Post-index period defined as the 180 days following therapy initiation, excluding index date
See also
  Status Clinical Trial Phase
Completed NCT01694680 - Intervention Trial in Early Age-related Macular Degeneration N/A
Completed NCT01224847 - Intravitreal Injection Anesthesia - Comparison of Different Topical Agents N/A
Withdrawn NCT04697953 - Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) Phase 3
Completed NCT05037396 - Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
Completed NCT00647439 - Genetics and Markers of Degenerative and Inflammatory Eye Diseases
Terminated NCT00902785 - A Study Of Early Markers Of Choroidal Neovascularization Phase 4
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Recruiting NCT03690505 - Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place N/A
Recruiting NCT03577041 - Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context
Completed NCT02445313 - Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device
Recruiting NCT00354445 - A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD Phase 4
Completed NCT05111743 - Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
Terminated NCT02398500 - Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT05146687 - Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
Completed NCT05110209 - Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
Not yet recruiting NCT05780931 - Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration
Recruiting NCT04292080 - Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy Phase 2
Recruiting NCT03859245 - Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention N/A
Completed NCT02022540 - Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD Phase 1
Completed NCT02585401 - Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada N/A